Ganoderma lucidum polysaccharides protect against MPP+ and rotenone-induced apoptosis in primary dopaminergic cell cultures through inhibiting oxidative stress

American Journal of Neurodegenerative Diseases

Volumn 5, Issue 2, 2016, Pages 131-144

  Guo, Shan Shan ^a   Cui, Xiao Lan ^a   Rausch, Wolf Dieter ^b  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Ganoderma lucidum polysaccharides; MPP+; Oxidative stress; Parkinson s disease; Rotenone

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; GANODERMA LUCIDUM EXTRACT; POLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TROLOX C; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; EMBRYO; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; GANODERMA LUCIDUM; IMMUNIZATION; IMMUNOREACTIVITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL DEGENERATION; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROPIDIUM IODIDE ASSAY; SPECTROPHOTOMETRY;

EID: 84980052866     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Camilleri A and Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson’s disease. CNS Neurosci Ther 2014; 20: 591-602.
2. Antony PM, Diederich NJ, Kruger R and Balling R. The hallmarks of Parkinson’s disease. FEBS J 2013; 280: 5981-5993.
3. da Conceicao FS, Ngo-Abdalla S, Houzel JC and Rehen SK. Murine model for Parkinson’s disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp 2010.
4. Choi DH, Cristovao AC, Guhathakurta S, Lee J, Joh TH, Beal MF and Kim YS. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson’s disease. Antioxid Redox Signal 2012; 16: 1033-1045.
5. Asaithambi A, Ay M, Jin H, Gosh A, Anantharam V, Kanthasamy A and Kanthasamy AG. Pro-tein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress. PLoS One 2014; 9: e96947.
6. Qin L, Liu Y, Hong JS and Crews FT. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 2013; 61: 855-868.
7. Berndt N, Bulik S and Holzhutter HG. Kinetic Modeling of the Mitochondrial Energy Meta-bolism of Neuronal Cells: The Impact of Reduced alpha-Ketoglutarate Dehydrogenase Activities on ATP Production and Generation of Reactive Oxygen Species. Int J Cell Biol 2012; 2012: 757594.
8. Yan MH, Wang X and Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 2013; 62: 90-101.
9. Guo C, Sun L, Chen X and Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res 2013; 8: 2003-2014.
10. Cai X, Jia H, Liu Z, Hou B, Luo C, Feng Z, Li W and Liu J. Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson’s disease. J Neurosci Res 2008; 86: 3622-3634.
11. Fiskum G, Starkov A, Polster BM and Chino-poulos C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson’s disease. Ann N Y Acad Sci 2003; 991: 111-119.
12. Dauer W and Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003; 39: 889-909.
13. Jenner P. Functional models of Parkinson’s disease: a valuable tool in the development of novel therapies. Ann Neurol 2008; 64 2: S16-S29.
14. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM and Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80: 4546-4550.
15. Tian YY, Jiang B, An LJ and Bao YM. Neuro-protective effect of catalpol against MPP(+)-induced oxidative stress in mesencephalic neurons. Eur J Pharmacol 2007; 568: 142-148.
16. Wang Y, Gao J, Miao Y, Cui Q, Zhao W, Zhang J and Wang H. Pinocembrin protects SH-SY5Y cells against MPP+-induced neurotoxicity through the mitochondrial apoptotic pathway. J Mol Neurosci 2014; 53: 537-545.
17. Hineno A, Kaneko K, Yoshida K and Ikeda S. Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochem Res 2011; 36: 2127-2135.
18. Verma R and Nehru B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem Int 2009; 55: 369-375.
19. Dukes AA, Korwek KM and Hastings TG. The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells. Antioxid Redox Signal 2005; 7: 630-638.
20. Gandhi S and Abramov AY. Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012; 2012: 428010.
21. Kim HG, Ju MS, Kim DH, Hong J, Cho SH, Cho KH, Park W, Lee EH, Kim SY and Oh MS. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson’s disease. Basic Clin Pharmacol Toxicol 2010; 107: 958-964.
22. Gaki GS and Papavassiliou AG. Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson’s disease. Neuromolecular Med 2014; 16: 217-230.
23. Bhardwaj N, Katyal P and Sharma AK. Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum. Recent Pat Inflamm Allergy Drug Discov 2014; 8: 104-117.
24. Suarez-Arroyo IJ, Rosario-Acevedo R, Aguilar-Perez A, Clemente PL, Cubano LA, Serrano J, Schneider RJ and Martinez-Montemayor MM. Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models. PLoS One 2013; 8: e57431.
25. Zhang W, Tao J, Yang X, Yang Z, Zhang L, Liu H, Wu K and Wu J. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem Biophys Res Commun 2014; 449: 307-312.
26. Zhang R, Xu S, Cai Y, Zhou M, Zuo X and Chan P. Ganoderma lucidum Protects Dopaminergic Neuron Degeneration through Inhibition of Microglial Activation. Evid Based Complement Alternat Med 2011; 2011: 156810.
27. Chen P, Yong Y, Gu Y, Wang Z, Zhang S and Lu L. Comparison of antioxidant and antiproliferation activities of polysaccharides from eight species of medicinal mushrooms. Int J Med Mushrooms 2015; 17: 287-295.
28. Donglin X. A rapid and optimal method to extracting polysaccharide from Ganoderma lucidum. Journal of China Central South Univer-sity of Forestry and Technology 2010; 30: 170-172.
29. Harshal A. Pawar PMDM. Spectrophotometric estimation of total polysaccharides in Cassia tora gum. Journal of Applied Pharmaceutical Science 2011; 1: 93-95.
30. Benzie IF and Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996; 239: 70-76.
31. Zhang X, Wang Y, Ma C, Yan Y, Yang Y, Wang X, Rausch WD. Ginsenoside Rd and ginsenoside Re offer neuroprotectionin a novel model of Parkinson’s disease. Am J Neurodegener Dis 2016; 5: 52-61.
32. Helmerhorst EJ, Murphy MP, Troxler RF and Oppenheim FG. Characterization of the mitochondrial respiratory pathways in Candida albicans. Biochim Biophys Acta 2002; 1556: 73-80.
33. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB and Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990; 55: 2142-2145.
34. Lecoeur H. Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases. Exp Cell Res 2002; 277: 1-14.
35. Hwang O. Role of oxidative stress in Parkinson’s disease. Exp Neurobiol 2013; 22: 11-17.
36. Lu C, Wei Y, Hu R, Wang Y, Li K and Li X. Transcranial Direct Current Stimulation Ameliorates Behavioral Deficits and Reduces Oxidative Stress in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mouse Model of Parkinson’s Disease. Neuromodulation 2015; 18: 442-6.
37. Durackova Z. Some current insights into oxidative stress. Physiol Res 2010; 59: 459-469.
38. Morroni F, Sita G, Tarozzi A, Cantelli-Forti G and Hrelia P. Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinsons disease. Brain Res 2014; 1589: 93-104.
39. Varcin M, Bentea E, Michotte Y and Sarre S. Oxidative stress in genetic mouse models of Parkinson’s disease. Oxid Med Cell Longev 2012; 2012: 624925.
40. Nakabeppu Y, Tsuchimoto D, Yamaguchi H and Sakumi K. Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 2007; 85: 919-934.
41. Soto-Otero R, Sanmartin-Suarez C, Sanchez-Iglesias S, Hermida-Ameijeiras A, Sanchez-Sellero I and Mendez-Alvarez E. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson’s disease. J Biochem Mol Toxicol 2006; 20: 209-220.
42. Pillai TG, Maurya DK, Salvi VP, Janardhanan KK and Nair CK. Fungal beta glucan protects radiation induced DNA damage in human lymphocytes. Ann Transl Med 2014; 2: 13.
43. Shi M, Zhang Z and Yang Y. Antioxidant and immunoregulatory activity of Ganoderma lucidum polysaccharide (GLP). Carbohydr Polym 2013; 95: 200-206.
44. Liu YJ, Du JL, Cao LP, Jia R, Shen YJ, Zhao CY, Xu P and Yin GJ. Anti-inflammatory and hepatoprotective effects of Ganoderma lucidum polysaccharides on carbon tetrachloride-induced hepatocyte damage in common carp (Cyprinus carpio L.). Int Immunopharmacol 2015; 25: 112-120.
45. Chen LW, Wang YQ, Wei LC, Shi M and Chan YS. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease. CNS Neurol Disord Drug Targets 2007; 6: 273-281.
46. Ding H, Zhou M, Zhang RP and Xu SL. Ganoderma lucidum extract protects dopaminergic neurons through inhibiting the production of inflammatory mediators by activated microglia.. Sheng Li Xue Bao 2010; 62: 547-554.
47. Liu Y, Zhang RY, Zhao J, Dong Z, Feng DY, Wu R, Shi M and Zhao G. Ginsenoside Rd Protects SH-SY5Y Cells against 1-Methyl-4-phenylpyri-dinium Induced Injury. Int J Mol Sci 2015; 16: 14395-14408.
48. Tseng YT, Chang FR and Lo YC. The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson’s toxin through enhancing antioxidative defense and preventing apoptotic death. Phytomedicine 2014; 21: 724-733.
49. Xu CL, Qu R, Zhang J, Li LF and Ma SP. Neuroprotective effects of madecassoside in early stage of Parkinson’s disease induced by MPTP in rats. Fitoterapia 2013; 90: 112-118.
50. Van Laar VS, Mishizen AJ, Cascio M and Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neuro-biol Dis 2009; 34: 487-500.
51. Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des 2014; 20: 5507-5509.
52. Strathearn KE, Yousef GG, Grace MH, Roy SL, Tambe MA, Ferruzzi MG, Wu QL, Simon JE, Lila MA and Rochet JC. Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinsons disease. Brain Res 2014; 1555: 60-77.
53. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-18622.
54. Tufekci KU, Civi Bayin E, Genc S and Genc K. The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson’s Disease. Parkinsons Dis 2011; 2011: 314082.
55. Reddehase S, Grumbt B, Neupert W and Hell K. The disulfide relay system of mitochondria is required for the biogenesis of mitochondrial Ccs1 and Sod1. J Mol Biol 2009; 385: 331-338.
56. Banerjee R, Starkov AA, Beal MF and Thomas B. Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta 2009; 1792: 651-663.
57. Winklhofer KF and Haass C. Mitochondrial dysfunction in Parkinson’s disease. Biochim Biophys Acta 2010; 1802: 29-44.
58. Zhai A, Zhu X, Wang X, Chen R and Wang H. Secalonic acid A protects dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP(+))-induced cell death via the mitochondrial apoptotic pathway. Eur J Pharmacol 2013; 713: 58-67.
59. Radad K, Rausch WD and Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int 2006; 49: 379-386.
60. Nataraj J, Manivasagam T, Justin Thenmozhi A and Essa MM. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress. Nutr Neurosci 2015; Epub ahead of print..
61. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T and Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 2005; 280: 42026-42035.
62. Xie Z, Ding SQ and Shen YF. Silibinin activates AMP-activated protein kinase to protect neuronal cells from oxygen and glucose deprivation-re-oxygenation. Biochem Biophys Res Commun 2014; 454: 313-319.